KARAS, Andreas Johannis,LONGSHAW, Christopher Mark
申请号：
MA39952
公开号：
MA39952B1
申请日:
2015.05.11
申请国别(地区):
MA
年份:
2018
代理人:
摘要：
the present invention relates to a compound of tiacumicine, stereoisomer, or a pharmaceutically acceptable solvate forms of it.a pharmaceutical composition containing the compound, and to tiacumicine, stereoisomer, or a pharmaceutically acceptable solvate forms of it.in the oral treatment of clostridium difficile infection (cdi) or diarrhea and clostridium difficile associated disease (cdad) (adc) in a patient with a dosage regimen in thegroup: administration of 200 mg of the compound of tiacumicine bid for 5 days followed by 5 days of rest, and 200 mg once daily for 10 days) and (ii).administration of 200 mg of the compound of tiacumicine bid for 5 days followed by a single dose of 200 mg every other day for 20 days.in addition,the present invention relates to a process for recovering a population of intestinal bifidobacteria in patients with clostridium difficile infection (cdi) or diarrhea, orclostridium difficile associated disease (cdad) (cd (ad) and to receive oral treatment with a compound of tiacumicine up to 50 to 90% of cases.the population of intestinal bifidobacteria, prior to the administration of the compound of tiacumicine on days 15 to 45 after the start of treatment.by the oral administration to the patient of tiacumicine compound on schedule is selected from the group mentioned above.La présente invention concerne un composé de tiacumicine, un stéréoisomère, un polymorphe ou un solvate pharmaceutiquement acceptable de celui-ci, et une composition pharmaceutique contenant un composé de tiacumicine, un stéréoisomère, un polymorphe ou un solvate pharmaceutiquement acceptable de celui-ci. Dans le traitement oral d'infections à clostridium difficile (cdi) ou de diarrhée ou maladie associée à clostridium difficile (cda) chez un patient conformément à un schéma posologique choisi dans le groupe comprenant: i. Administration de 200 mg du composé de tiacumicine bid pendant 5 jours suivis de 5 jours de repos, puis de 200 mg une fois par jour pendant 10 jours
